EOLS Stock Down -36% after 5-Day Loss Streak
Evolus (EOLS) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -36% return. The company has lost about $135 Mil in value over the last 5 days, with its current market capitalization at about $381 Mil. The stock remains 46.6% below its value at the end of 2024. This compares with year-to-date returns of 8.6% for the S&P 500.
EOLS provides medical aesthetic products, including a proprietary botulinum toxin formulation for treating moderate to severe glabellar lines in adults, serving physicians and patients in the U.S. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell EOLS.
Comparing EOLS Stock Returns With The S&P 500
The following table summarizes the return for EOLS stock vs. the S&P 500 index over different periods, including the current streak:
- Does Exxon Mobil Stock Still Have Room to Run?
- Is Royal Caribbean Stock Undervalued Stock Or Value Trap?
- What Is Happening With Rocket Lab Stock?
- Brookfield Earnings Driven By Fundraising Engine And AI Tailwinds.
- Catalysts That Could Propel Tesla Stock to the Moon
- Cash Machine Trading Cheap – Abercrombie & Fitch Stock Set to Run?
| Return Period | EOLS | S&P 500 |
|---|---|---|
| 1D | -2.8% | 0.8% |
| 5D (Current Streak) | -35.5% | 2.4% |
| 1M (21D) | -39.4% | 1.7% |
| 3M (63D) | -41.5% | 12.8% |
| YTD 2025 | -46.6% | 8.6% |
| 2024 | 4.8% | 23.3% |
| 2023 | 40.2% | 24.2% |
| 2022 | 15.4% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: EOLS Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 60 S&P constituents with 3 days or more of consecutive gains and 48 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 36 | 27 |
| 4D | 4 | 19 |
| 5D | 14 | 0 |
| 6D | 5 | 0 |
| 7D or more | 1 | 2 |
| Total >=3 D | 60 | 48 |
Key Financials for Evolus (EOLS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $202.1 Mil | $266.3 Mil |
| Operating Income | $-45.0 Mil | $-27.2 Mil |
| Net Income | $-61.7 Mil | $-50.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $68.5 Mil | $69.4 Mil |
| Operating Income | $-13.0 Mil | $-14.1 Mil |
| Net Income | $-18.9 Mil | $-17.1 Mil |
The losing streak EOLS stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.